The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells
Abstract
PURPOSE: Provenge (Dendreon Corp, Seattle, WA) is an immunotherapy product consisting of autologous dendritic cells loaded ex vivo with a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) linked to granulocyte-macrophage colony-stimulating factor. Sequential phase I and phase II trials were performed to determine the safety and efficacy of Provenge and to assess its capacity to break immune tolerance to the normal tissue antigen PAP. PATIENTS AND METHODS: All patients had hormone-refractory prostate cancer. Dendritic-cell precursors were harvested by leukapheresis in weeks 0, 4, 8, and 24, loaded ex vivo with antigen for 2 days, and then infused intravenously over 30 minutes. Phase I patients received increasing doses of Provenge, and phase II patients received all the Provenge that could be prepared from a leukapheresis product. RESULTS: Patients tolerated treatment well. Fever, the most common adverse event, occurred after 15 infusions (14.7%). All patients developed immune responses to the recombinant fusion protein used to prepare Provenge, and 38% developed immune responses to PAP. Three patients had a more than 50% decline in prostate-specific antigen (PSA) level, and another three patients had 25% to 49% decreases in PSA. The time to disease progression correlated with development of an immune response to PAP and with the dose of dendritic cells received. CONCLUSION: Provenge is a novel immunotherapy agent that is safe and breaks tolerance to the tissue antigen PAP. Preliminary evidence for clinical efficacy warrants further exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kugler, A., Stuhler, G., Walden, P., Zöller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Müller, C. A., Becker, V., et al. (2000) · Nature Medicine · doi:10.1038/73193 · Cited by 639
RetractedDendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Functional diversity of helper T lymphocytes
Abbas, A. K., Murphy, K. M., & Sher, A. (1996) · Nature · doi:10.1038/383787a0 · Cited by 4,450
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationPeptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., & Falo, L. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.283 · Cited by 717
Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V, Schwartz, M., & Fossa, S. D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.607 · Cited by 385
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Self-citationCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Decisions About Dendritic Cells: Past, Present, and Future
Steinman, R. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100311-102839 · Cited by 1,274
Dendritic cells as therapeutic vaccines against cancer
Banchereau, J., & Palucka, A. K. (2005) · Nature Reviews Immunology · doi:10.1038/nri1592 · Cited by 1,204
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Self-citationDendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2017) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 927
Higano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J., Yuh, L., Provost, N., & Frohlich, M. W. (2009) · Cancer · doi:10.1002/cncr.24429 · Cited by 810
Self-citationPROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
The use of dendritic cells in cancer immunotherapy
Schuler, G., Schuler-Thurner, B., & Steinman, R. M. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00015-3 · Cited by 631
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214364 · Cited by 562
Dendritic cell subsets in health and disease
Ueno, H., Klechevsky, E., Morita, R., Aspord, C., Cao, T., Matsui, T., Di Pucchio, T., Connolly, J., Fay, J. W., Pascual, V., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00551.x · Cited by 430
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407
Self-citationCancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., & Anichini, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.805 · Cited by 401
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01725-x · Cited by 389
Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M., & Figdor, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1399 · Cited by 377
Spinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M. P., & Rivoltini, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl158 · Cited by 300
Active immunization against cancer with dendritic cells: The near future
Steinman, R. M., & Dhodapkar, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1503 · Cited by 299
Some interfaces of dendritic cell biology
STEINMAN, R. M. (2003) · APMIS · doi:10.1034/j.1600-0463.2003.11107802.x · Cited by 292
Dendritic cells: On the move from bench to bedside
Nestle, F. O., Banchereau, J., & Hart, D. (2001) · Nature Medicine · doi:10.1038/89863 · Cited by 287
Palmer, D. H., Midgley, R. S., Mirza, N., Torr, E. E., Ahmed, F., Steele, J. C., Steven, N. M., Kerr, D. J., Young, L. S., & Adams, D. H. (2009) · Hepatology · doi:10.1002/hep.22626 · Cited by 286
The First 1000 Dendritic Cell Vaccinees
Ridgway, D. (2003) · Cancer Investigation · doi:10.1081/cnv-120025091 · Cited by 278
Sheikh, N. A., Petrylak, D., Kantoff, P. W., dela Rosa, C., Stewart, F. P., Kuan, L.-Y., Whitmore, J. B., Trager, J. B., Poehlein, C. H., Frohlich, M. W., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1317-2 · Cited by 263
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
Khoury, H. J., Collins, R. H., Blum, W., Stiff, P. S., Elias, L., Lebkowski, J. S., Reddy, A., Nishimoto, K. P., Sen, D., Wirth, E. D., et al. (2017) · Cancer · doi:10.1002/cncr.30696 · Cited by 102
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
“The PAP protein can be detected in two forms, cellular (cPAP) or secretory (sPAP), differentiated by posttranscriptional modifications [109].”
BackgroundMethodInfluentialDendritic cells as cancer therapeutics
Bryant, C. E., Sutherland, S., Kong, B., Papadimitrious, M. S., Fromm, P. D., & Hart, D. N. J. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2018.02.015 · Cited by 61
Metadata
- Authors
- Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., & Valone, F. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-12-01
- Volume
- 18
- Issue
- 23
- Pages
- 3894-3903
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2261691410
- Cited by
- 625
- References
- 19
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.